NCT04772365View on ClinicalTrials.gov

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 10, 2021

Study Completion Date

December 10, 2021

Conditions
Asthma
Interventions
DRUG

SHR-1819

SHR-1819 will be subcutaneously administered with different dose levels;

DRUG

Placebo

Placebo will be subcutaneously administered with different dose levels;

Trial Locations (1)

410013

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

NCT04772365 - A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects | Biotech Hunter | Biotech Hunter